PL2935238T3 - Sprzężone arylowe i heteroarylowe laktamy - Google Patents

Sprzężone arylowe i heteroarylowe laktamy

Info

Publication number
PL2935238T3
PL2935238T3 PL13817739T PL13817739T PL2935238T3 PL 2935238 T3 PL2935238 T3 PL 2935238T3 PL 13817739 T PL13817739 T PL 13817739T PL 13817739 T PL13817739 T PL 13817739T PL 2935238 T3 PL2935238 T3 PL 2935238T3
Authority
PL
Poland
Prior art keywords
aryl
heteroaryl fused
fused lactams
lactams
heteroaryl
Prior art date
Application number
PL13817739T
Other languages
English (en)
Inventor
Martin Paul Edwards
Robert Arnold Kumpf
Pei-Pei Kung
Indrawan James Mcalpine
Sacha Ninkovic
Eugene Yuanjin Rui
Scott Channing Sutton
John Howard Tatlock
Martin James Wythes
Luke Raymond Zehnder
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of PL2935238T3 publication Critical patent/PL2935238T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL13817739T 2012-12-21 2013-12-05 Sprzężone arylowe i heteroarylowe laktamy PL2935238T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261740596P 2012-12-21 2012-12-21
EP13817739.9A EP2935238B1 (en) 2012-12-21 2013-12-05 Aryl and heteroaryl fused lactams
PCT/IB2013/060682 WO2014097041A1 (en) 2012-12-21 2013-12-05 Aryl and heteroaryl fused lactams

Publications (1)

Publication Number Publication Date
PL2935238T3 true PL2935238T3 (pl) 2018-05-30

Family

ID=49917684

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17206218T PL3339303T3 (pl) 2012-12-21 2013-12-05 Arylowe i heteroarylowe sprzężone laktamy
PL13817739T PL2935238T3 (pl) 2012-12-21 2013-12-05 Sprzężone arylowe i heteroarylowe laktamy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL17206218T PL3339303T3 (pl) 2012-12-21 2013-12-05 Arylowe i heteroarylowe sprzężone laktamy

Country Status (46)

Country Link
US (3) US9040515B2 (pl)
EP (2) EP3339303B9 (pl)
JP (1) JP5909308B2 (pl)
KR (1) KR101712441B1 (pl)
CN (1) CN104870435B (pl)
AP (1) AP2015008574A0 (pl)
AR (1) AR094174A1 (pl)
AU (1) AU2013365908C1 (pl)
BR (1) BR112015014678B1 (pl)
CA (1) CA2893339C (pl)
CL (1) CL2015001733A1 (pl)
CR (2) CR20200273A (pl)
CU (1) CU24414B1 (pl)
CY (2) CY1119883T1 (pl)
DK (2) DK2935238T3 (pl)
DO (1) DOP2015000157A (pl)
EA (1) EA028317B1 (pl)
EC (1) ECSP15031579A (pl)
ES (2) ES2808987T3 (pl)
GE (1) GEP201706718B (pl)
GT (1) GT201500190A (pl)
HR (2) HRP20180060T1 (pl)
HU (2) HUE050009T2 (pl)
IL (1) IL239520B (pl)
LT (2) LT3339303T (pl)
MA (1) MA38175B1 (pl)
MD (1) MD4664C9 (pl)
ME (2) ME03793B (pl)
MX (2) MX2015008058A (pl)
MY (2) MY192259A (pl)
NO (1) NO2961649T3 (pl)
NZ (1) NZ708801A (pl)
PE (1) PE20151090A1 (pl)
PH (1) PH12015501367B1 (pl)
PL (2) PL3339303T3 (pl)
PT (2) PT3339303T (pl)
RS (2) RS60582B9 (pl)
SG (1) SG11201504076XA (pl)
SI (2) SI3339303T1 (pl)
TN (1) TN2015000281A1 (pl)
TR (1) TR201802791T4 (pl)
TW (1) TWI546293B (pl)
UA (1) UA111305C2 (pl)
UY (2) UY35225A (pl)
WO (1) WO2014097041A1 (pl)
ZA (1) ZA201504437B (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US9085583B2 (en) 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US9243022B2 (en) 2012-12-21 2016-01-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
AP2016009605A0 (en) * 2014-06-17 2016-12-31 Pfizer Substituted dihydroisoquinolinone compounds
WO2015193768A1 (en) * 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
MA40848A (fr) * 2014-10-28 2021-05-05 Glaxosmithkline Ip No 2 Ltd Inhibiteurs d'ezh2 (enhancer of zeste homolog 2)
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ｅｚｈ２抑制劑
WO2016101956A2 (en) 2014-12-23 2016-06-30 University Of Copenhagen Treatment of cancer by inhibiting ezh2 activity
UA120960C2 (uk) * 2015-03-27 2020-03-10 Сінгента Партісіпейшнс Аг Мікробіоцидні гетеробіциклічні похідні
TW201708210A (zh) * 2015-06-30 2017-03-01 葛蘭素史克智慧財產（第二）有限公司 Ｚｅｓｔｅ同源物２增強子之抑制劑
TW201718598A (zh) * 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
SI3378859T1 (sl) 2015-11-19 2020-03-31 Jiangsu Hengrui Medicine Co., Ltd., Derivat benzofurana, postopek za njegovo pripravo in njegova uporaba v medicini
WO2017191545A1 (en) * 2016-05-05 2017-11-09 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
WO2018075598A1 (en) 2016-10-19 2018-04-26 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
US20200262813A1 (en) * 2016-11-11 2020-08-20 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. 1,5,7-trisubstituted isoquinoline derivatives, preparation thereof, and use thereof in medicines
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
EP3626239B1 (en) 2017-05-18 2024-07-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Ezh2 inhibitor combined with btk inhibitor for treating tumor
EP3626715A4 (en) 2017-05-18 2021-03-24 Jiangsu Hengrui Medicine Co., Ltd. CRYSTAL OF A BENZOFURAND DERIVATIVE-FREE BASE AND MANUFACTURING PROCESS
CN106977483A (zh) * 2017-06-02 2017-07-25 遵义医学院 一种二氟烷基取代的黄酮醇、异黄酮醇和香豆素类化合物的合成方法
US11529344B2 (en) 2017-11-14 2022-12-20 Pfizer Inc. EZH2 inhibitor combination therapies
DK3746446T3 (da) 2018-01-31 2022-06-27 Mirati Therapeutics Inc PRC2-inhibitorer
EP3813784B1 (en) * 2018-06-07 2024-01-10 The Regents Of The University Of Michigan Prc1 inhibitors and prc1 inhibitors for use in methods of treatment therewith
WO2020011607A1 (en) 2018-07-09 2020-01-16 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
EP3870173A4 (en) * 2018-10-24 2022-06-22 Vanderbilt University WDR5 INHIBITORS AND MODULATORS
CN111320582A (zh) * 2018-12-17 2020-06-23 江苏恩华药业股份有限公司 一种类酰胺类衍生物及其中间体的制备方法
KR102689665B1 (ko) * 2019-02-19 2024-07-31 한미약품 주식회사 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도
US12421228B2 (en) 2019-04-22 2025-09-23 Mirati Therapeutics, Inc. Naphthyridine derivatives as PRC2 inhibitors
US12577227B2 (en) 2019-06-04 2026-03-17 Vanderbilt University WDR5 inhibitors and modulators
CN114269748A (zh) 2019-06-05 2022-04-01 米拉蒂医疗股份有限公司 作为用于治疗癌症的PRC2抑制剂的咪唑并[1,2-c]嘧啶衍生物
US12692249B2 (en) 2019-11-08 2026-07-28 Vanderbilt University WDR5 inhibitors and modulators
KR102386403B1 (ko) 2020-08-13 2022-04-15 한미약품 주식회사 신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도
WO2022179584A1 (zh) * 2021-02-26 2022-09-01 南京药石科技股份有限公司 新型ezh2抑制剂及其用途
JP2026500298A (ja) 2022-12-15 2026-01-06 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺有害生物剤として有用である新規な二環式カルボキサミド化合物
CN118978498B (zh) * 2024-10-22 2025-04-01 浙江雅辰药物科技股份有限公司 一种5-羟甲基四氢呋喃-3-醇的制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846412A (en) 1971-03-18 1974-11-05 Lepetit Spa Dihydro-2-amino-isoquinolines and their derivatives
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
EP1940819A1 (en) 2005-08-16 2008-07-09 Memory Pharmaceuticals Corporation Phosphodiesterase 10 inhibitors
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
US20110251216A1 (en) 2010-02-19 2011-10-13 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
WO2012005805A1 (en) 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
US8846935B2 (en) 2010-05-07 2014-09-30 Glaxosmithkline Llc Indazoles
MX2012012966A (es) 2010-05-07 2013-01-22 Glaxosmithkline Llc Indoles.
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
EP2627648A1 (en) 2010-09-16 2013-08-21 Novartis AG 17aHYDROXYLASE/C17,20-LYASE INHIBITORS
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2012118812A2 (en) * 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) * 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
US9730925B2 (en) 2011-09-30 2017-08-15 Glaxomithkline Llc Methods of treating cancer
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
JP6254169B2 (ja) 2012-09-28 2017-12-27 ファイザー・インク ベンズアミドおよびヘテロベンズアミド化合物
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
UA111305C2 (uk) * 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
US9243022B2 (en) 2012-12-21 2016-01-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
FR3000059A1 (fr) 2012-12-21 2014-06-27 Saint Gobain Placo Composition pour plaques de platre et produits obtenus
US9604930B2 (en) 2012-12-21 2017-03-28 Epizyme, Inc. Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof
NZ708175A (en) 2012-12-21 2020-06-26 Hoffmann La Roche Peptides as oxytocin agonists
FR3000065A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
ME03000B (me) 2012-12-21 2018-10-20 Plexxikon Inc Jedinjenja i metode modulacije kinaze i povezane indikacije
AP2016009605A0 (en) 2014-06-17 2016-12-31 Pfizer Substituted dihydroisoquinolinone compounds

Also Published As

Publication number Publication date
PE20151090A1 (es) 2015-08-07
CU24414B1 (es) 2019-05-03
EP2935238B1 (en) 2017-12-27
NO2961649T3 (pl) 2018-02-17
CN104870435B (zh) 2016-12-07
TW201446753A (zh) 2014-12-16
US10246433B2 (en) 2019-04-02
RS60582B1 (sr) 2020-08-31
MY192259A (en) 2022-08-12
MY176307A (en) 2020-07-28
TR201802791T4 (tr) 2018-03-21
MX2015008058A (es) 2015-10-30
MA38175B1 (fr) 2018-11-30
CA2893339A1 (en) 2014-06-26
MD4664C9 (ro) 2020-07-31
RS60582B9 (sr) 2021-09-30
PL3339303T3 (pl) 2021-01-25
CN104870435A (zh) 2015-08-26
ZA201504437B (en) 2016-07-27
LT3339303T (lt) 2020-09-10
DOP2015000157A (es) 2015-11-30
AR094174A1 (es) 2015-07-15
ES2808987T9 (es) 2021-11-29
ES2658974T3 (es) 2018-03-13
CY1119883T1 (el) 2018-06-27
AU2013365908C1 (en) 2018-01-25
IL239520A0 (en) 2015-08-31
BR112015014678B1 (pt) 2021-12-07
AU2013365908B2 (en) 2017-07-20
ES2808987T3 (es) 2021-03-02
CY1123237T1 (el) 2021-10-29
US9040515B2 (en) 2015-05-26
ME02980B (me) 2018-10-20
BR112015014678A2 (pt) 2017-07-11
AU2013365908A1 (en) 2015-06-11
PT2935238T (pt) 2018-02-09
SG11201504076XA (en) 2015-06-29
PH12015501367A1 (en) 2015-09-02
JP5909308B2 (ja) 2016-04-26
UY38712A (es) 2020-06-30
ECSP15031579A (es) 2017-08-31
PH12015501367B1 (en) 2018-08-03
AP2015008574A0 (en) 2015-07-31
UA111305C2 (uk) 2016-04-11
SI2935238T1 (en) 2018-04-30
WO2014097041A1 (en) 2014-06-26
US20140179667A1 (en) 2014-06-26
CL2015001733A1 (es) 2015-10-23
GT201500190A (es) 2016-01-21
HK1208866A1 (en) 2016-03-18
RS56815B1 (sr) 2018-04-30
MX2020002924A (es) 2020-07-22
HUE050009T2 (hu) 2020-11-30
CU20150062A7 (es) 2015-11-27
PT3339303T (pt) 2020-07-30
HUE038238T2 (hu) 2018-10-29
EP3339303B9 (en) 2021-07-21
TN2015000281A1 (fr) 2016-10-03
US20150175572A1 (en) 2015-06-25
EP3339303B1 (en) 2020-06-24
UY35225A (es) 2014-07-31
MD4664B1 (ro) 2019-12-31
KR101712441B1 (ko) 2017-03-07
HRP20180060T1 (hr) 2018-02-23
GEP201706718B (en) 2017-08-10
DK2935238T3 (en) 2018-01-22
EP2935238A1 (en) 2015-10-28
LT2935238T (lt) 2018-02-26
US20170233368A1 (en) 2017-08-17
CR20150279A (es) 2015-09-03
IL239520B (en) 2018-05-31
NZ708801A (en) 2018-08-31
EA201590879A1 (ru) 2015-12-30
EA028317B1 (ru) 2017-11-30
EP3339303A1 (en) 2018-06-27
KR20150100823A (ko) 2015-09-02
TWI546293B (zh) 2016-08-21
HRP20201194T1 (hr) 2020-11-13
DK3339303T3 (da) 2020-08-10
CA2893339C (en) 2017-06-13
JP2016507497A (ja) 2016-03-10
MA38175A1 (fr) 2018-08-31
HRP20201194T2 (hr) 2021-09-17
CR20200273A (es) 2020-09-23
ME03793B (me) 2021-04-20
SI3339303T1 (sl) 2020-09-30
MD20150052A2 (ro) 2015-12-31

Similar Documents

Publication Publication Date Title
HRP20201194T1 (hr) Laktami kondenzirani s arilom i heteroarilom
EP2935226A4 (en) HETEROARYL COMPOUNDS AND USES THEREOF
SG11201500927YA (en) Kimono
GB201200022D0 (en) Surveillance
ZA201503367B (en) Heteroaryl derivatives and uses thereof
SG11201403852UA (en) Fused pyrroledicarboxamides and their use as pharmaceuticals
ZA201504122B (en) Diazole lactams
EP2877926A4 (en) SAFETY TESTING OF AN APPLICATION
AP3611A (en) Heterocyclic compounds and their uses
EP2894722A4 (en) THICK HEADED
EP2820499A4 (en) PROGRAMMABLE SENSORS
GB2505195B (en) Joint configuration
AU4710P (en) Fusion xTriticosecale
GB201215901D0 (en) Protein modification
GB201209803D0 (en) MK-V fusion system
GB201223020D0 (en) Tmf
GB201207694D0 (en) Mirror mate